CAS 905854-02-6

Tivantinib

Description:

Tivantinib, also known by its chemical name ARQ 197, is a small molecule inhibitor primarily targeting the MET receptor tyrosine kinase, which plays a crucial role in various cellular processes, including proliferation, survival, and migration. It is characterized by its ability to interfere with MET signaling pathways, making it a candidate for cancer treatment, particularly in tumors that exhibit MET overexpression or mutations. Tivantinib has been investigated in clinical trials for its efficacy in treating various cancers, including non-small cell lung cancer and hepatocellular carcinoma. The compound is typically administered orally and has a specific pharmacokinetic profile, including absorption, distribution, metabolism, and excretion characteristics that influence its therapeutic potential. Its safety and side effect profile are also important considerations in clinical settings. As a research compound, Tivantinib exemplifies the ongoing efforts to develop targeted therapies in oncology, aiming to improve treatment outcomes for patients with MET-related malignancies.

Formula: C₂₃H₁₉N₃O₂

InChI: InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1

InChI key: InChIKey=UCEQXRCJXIVODC-PMACEKPBSA-N

SMILES: O=C1[C@@H](C=2C=3C=4N(C2)CCCC4C=CC3)[C@@H](C(=O)N1)C=5C=6C(NC5)=CC=CC6

Synonyms:

• (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]chinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidin-2,5-dion
• (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione
• (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
• 2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-
• Arq 197
• Tivantinib

(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione

CAS: 905854-02-6

Formula: C₂₃H₁₉N₃O₂

Purity: 99%

Color and Shape: Solid

Molecular weight: 369.4159

Ref: IN-DA0036UK

Tivantinib

CAS: 905854-02-6

Tivantinib

Purity: ≥98%

Molecular weight: 369.42g/mol

Ref: 54-BUP10434

Tivantinib

CAS: 905854-02-6

Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.

Formula: C₂₃H₁₉N₃O₂

Purity: 98% - 99.41%

Color and Shape: Solid

Molecular weight: 369.42

Ref: TM-T6117

Tivantinib

Controlled Product

CAS: 905854-02-6

Applications Tivantinib is a hepatocyte growth factor receptor (proto-oncogene c-Met; MET) inhibitor. Tivantinib inhibits human c-Met receptor tyrosine kinase selectively and is a promising therapeutic option for the treatment of c-Met-associated cancers. Potent c-MET inhibitor.
References Pento, J.T. et al.: Drugs Fut., 36, 893 (2011); Munshi, N. et al.: Mol. Cancer Ther., 9, 1544 (2010); Bagai, R. et al.: IDrugs, 13, 404 (2010);

Formula: C₂₃H₁₉N₃O₂

Color and Shape: Neat

Molecular weight: 369.42

Ref: TR-T447200

Tivantinib

CAS: 905854-02-6

Inhibitor of MET receptor tyrosine kinase

Formula: C₂₃H₁₉N₃O₂

Purity: Min. 95%

Molecular weight: 369.42 g/mol

Ref: 3D-FT44530